Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter?

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left">Day part</td><td align="center">Value</td><td align="center">Mean (SD)</td><td align="center">Median</td><td align="center">Min–max</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left" rowspan="3">Morning</td><td align="center">Baseline value (0 h)</td><td align="center">111.4 (49.7)</td><td align="center">107.5</td><td align="center">38.4–232</td></tr><tr><td align="center">Concentration (2 h)</td><td align="center">344.7 (146.9)</td><td align="center">330.0</td><td align="center">145–693</td></tr><tr><td align="center">Difference</td><td align="center">233.3 (114.9)</td><td align="center">214.0</td><td align="center">91.0–546</td></tr><tr><td align="left" colspan="5"><hr/></td></tr><tr><td align="left" rowspan="3">Evening</td><td align="center">Baseline value (0 h)</td><td align="center">86.9 (41.1)</td><td align="center">78.4</td><td align="center">38.5–182</td></tr><tr><td align="center">Concentration (2 h)</td><td align="center">215.3 (126.4)</td><td align="center">218.0</td><td align="center">51.3–402</td></tr><tr><td align="center">Difference</td><td align="center">128.5 (109.8)</td><td align="center">133.6</td><td align="center">−16.0–313.5</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Descriptive statistics, Day 7 concentrations (ng/mL), 0 h and 2 h after dose.

International Scholarly Research Notices

tab2

Table 2

Table 2: Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter? 

Table 2 | Metabotropic Glutamate Receptor 5 Negative Modulation in Phase I Clinical Trial: Potential Impact of Circadian Rhythm on the Neuropsychiatric Adverse Reactions—Do Hallucinations Matter? 